Kane Biotech Inc.
KNE.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.77M | 1.52M | 1.47M | 554.50K | 122.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.77M | 1.52M | 1.47M | 554.50K | 122.60K |
| Cost of Revenue | 1.13M | 881.80K | 746.90K | 218.70K | 32.70K |
| Gross Profit | 640.50K | 640.60K | 728.10K | 335.90K | 89.90K |
| SG&A Expenses | 2.33M | 2.26M | 2.66M | 2.47M | 1.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.42M | 4.24M | 4.53M | 3.89M | 2.83M |
| Operating Income | -2.65M | -2.72M | -3.06M | -3.33M | -2.71M |
| Income Before Tax | -3.01M | -3.27M | -3.61M | -4.04M | -3.66M |
| Income Tax Expenses | -936.00K | -936.00K | -- | -- | -- |
| Earnings from Continuing Operations | -2.07 | -2.33 | -3.61 | -4.04 | -3.66 |
| Earnings from Discontinued Operations | 6.72M | 6.79M | 7.68M | 7.53M | -213.10K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.64M | 4.46M | 4.07M | 3.48M | -3.88M |
| EBIT | -2.65M | -2.72M | -3.06M | -3.33M | -2.71M |
| EBITDA | -2.54M | -2.58M | -2.93M | -3.19M | -2.57M |
| EPS Basic | 0.04 | 0.03 | 0.03 | 0.03 | -0.03 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | 0.02 | 0.02 | 0.02 | 0.02 | -0.03 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 553.82M | 535.61M | 529.89M | 522.90M | 515.47M |
| Average Diluted Shares Outstanding | 579.48M | 561.27M | 555.55M | 548.56M | 536.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |